Selpercatinib Shifts Treatment Paradigm for MTC and NSCLC

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Medullary thyroid cancer (MTC) and non-small cell lung cancer (NSCLC) can be driven by alterations in the RET proto-oncogene.
• Targeted therapies offer a promising approach for cancers with specific genetic mutations.

Purpose of the Study:

• To evaluate the efficacy of the RET inhibitor selpercatinib compared to standard of care in patients with RET-altered MTC and NSCLC.
• To underscore the clinical utility of comprehensive tumor genomic profiling.

Main Methods:

• Separate clinical trials were conducted to assess selpercatinib in distinct patient cohorts.
• Patients included those with advanced or metastatic MTC and NSCLC harboring RET mutations or fusions.

Main Results:

• Selpercatinib demonstrated superior outcomes compared to standard of care in both RET-mutated MTC and RET fusion-positive NSCLC.
• Further follow-up is required to fully ascertain long-term efficacy and safety.

Conclusions:

• Selpercatinib represents a significant advancement in treating RET-driven MTC and NSCLC.
• Routine tumor sequencing is essential for identifying eligible patients and guiding treatment decisions.